TD Waterhouse Canada Inc. Has $15.30 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

TD Waterhouse Canada Inc. grew its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,313 shares of the biopharmaceutical company's stock after acquiring an additional 16,293 shares during the period. TD Waterhouse Canada Inc.'s holdings in Bristol-Myers Squibb were worth $15,297,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of BMY. Tower Research Capital LLC TRC lifted its stake in Bristol-Myers Squibb by 89.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 123,999 shares of the biopharmaceutical company's stock worth $7,013,000 after acquiring an additional 58,625 shares during the last quarter. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $28,000. Mirabella Financial Services LLP acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $1,692,000. MML Investors Services LLC increased its holdings in Bristol-Myers Squibb by 15.4% in the fourth quarter. MML Investors Services LLC now owns 362,028 shares of the biopharmaceutical company's stock valued at $20,476,000 after buying an additional 48,340 shares during the last quarter. Finally, MetLife Investment Management LLC raised its stake in Bristol-Myers Squibb by 1.8% in the fourth quarter. MetLife Investment Management LLC now owns 536,833 shares of the biopharmaceutical company's stock valued at $30,363,000 after buying an additional 9,631 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded down $0.83 during midday trading on Friday, hitting $47.86. 16,292,011 shares of the stock traded hands, compared to its average volume of 13,089,626. The business's 50 day moving average price is $56.50 and its two-hundred day moving average price is $56.50. The firm has a market capitalization of $97.38 billion, a PE ratio of -10.83, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.55 by $0.25. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. During the same quarter last year, the company earned ($4.40) EPS. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.18%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently -56.11%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BMY. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a report on Tuesday. They set an "overweight" rating and a $65.00 price objective on the stock. Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Insiders Place Their Bets

In related news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction dated Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.